NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Free peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it for free.

Test my supply
+17 more ↓
87%
Finnrick rating
#82 of 140 GHK-Cu vendors
33 of 38 classifiable tests passed
customers 4.7★ (18)
methodology · Purity focus
Finnrick analysis · GHK-Cu

Qing Li Peptide's GHK-Cu has a mixed purity-focus record, with a May 99.4% purity miss and two early sub-99.5% results despite many clean passes. June retests recovered, but fill history includes a -40% outlier and uneven batch detail.

methodology →
vendor intelligence report
Vendor Intelligence Report: Qing Li Peptide

Domain records, Wayback captures and supplier profiles point away from the Hong Kong-facing history Qing Li presents. The report maps cloned storefronts, exposed staff records and a Pioneer Peptide fee pattern seen in buyer reports.

33 pages6 risk factors assessed3 Jul 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cuselected
$0.05
87%
38
2
Retatrutide
$0.97
80%
127
3
Tirzepatide
$0.47
80%
44
4
Ipamorelin
$0.60
70%
16
5
PT-141
-
68%
7
6
Semaglutide
$1.20
68%
3
7
Melanotan II
$0.40
66%
7
8
Cagrilintide
$1.80
54%
4
9
Sermorelin
$5.00
50%
6
10
Survodutide
$3.00
48%
3
11
BPC-157
$0.70
40%
34
12
CJC-1295
$1.40
35%
19
13
Tesamorelin
$1.80
35%
24
14
MOTS-c
$0.50
27%
5
15
TB-500
$1.20
23%
19
16
Epithalon
$0.50
-
0
17
GLOW
-
-
0
18
HGH
-
-
0
19
KLOW
$0.21
-
0
20
KPV
-
-
0
21
NAD+
$0.02
-
0
22
Pinealon
$0.45
-
0
23
SS-31
$0.44
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%10 Jul 2025: 87%16 Jul 2025: 86%16 Jul 2025: 82%16 Jul 2025: 78%16 Jul 2025: 79%4 Aug 2025: 80%4 Aug 2025: 81%21 Aug 2025: 82%21 Aug 2025: 83%4 Sep 2025: 84%8 Sep 2025: 85%20 Sep 2025: 84%23 Sep 2025: 85%3 Oct 2025: 86%21 Oct 2025: 87%23 Oct 2025: 88%7 Nov 2025: 88%17 Nov 2025: 84%25 Nov 2025: 85%17 Dec 2025: 86%6 Jan 2026: 86%6 Jan 2026: 87%26 Jan 2026: 88%2 Feb 2026: 88%4 Feb 2026: 88%18 Feb 2026: 89%2 Mar 2026: 89%2 Mar 2026: 90%4 Mar 2026: 90%18 Mar 2026: 90%18 Mar 2026: 91%13 May 2026: 88%2 Jun 2026: 88%8 Jun 2026: 89%23 Jun 2026: 89%9 Aug 2026: 89%25 Aug 2026: 89%15 Sep 2026: 87%29 Sep 2026: current 87%87%86%87%Jul 25Sep 26
Showing GHK-Cu tests only
Free peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it for free.

Test my supply
Qing Li Peptide GHK-Cu test history
COA-backed lab tests
1-10 of 38

About Qing Li Peptide test results from Finnrick

Qing Li Peptide is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 15 peptides and 356 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Qing Li Peptide peptides in this dataset are BPC-157 (34 tests), Cagrilintide (4 tests) and CJC-1295 (19 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests. It also includes 1 correction related to this vendor.

Corrections
2026-03-04
Customer update
Sample potency on sample fz959qa was incorrectly captured as 0.10 mg, correct quantity was 10 mg.
Free peptide testing

Ordered GHK-Cu from Qing Li Peptide? Mail in a sample (US only) and let us test it for free.

Test my supply